On April 6, 2023 Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, reported that the Company will participate at several conferences in April 2023 (Press release, Carisma Therapeutics, APR 6, 2023, View Source [SID1234629869]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Upcoming healthcare industry conferences include:

2023 Cell & Gene Meeting on the Med

Tom Wilton, Chief Business Officer, will give a corporate presentation.
Thursday, April 13, 2023 at 10:45 am CET
Barcelona, Spain
American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023

Carisma will present three data abstracts during the meeting:
Macrophages engineered with cytokine switch receptors: Development of a modular platform for rebalancing inflammation in microenvironments;
A mesothelin targeting chimeric antigen receptor macrophage (CAR-M) for solid tumor immunotherapy: pre-clinical development of CT-1119; and
A Phase 1, First-in-Human study of autologous anti-HER2 CAR-M in participants with HER2 overexpressing solid tumors.
Friday, April 14 to Wednesday, April 19, 2023
Orlando, Florida
Upcoming investor conferences include:

Needham 22nd Annual Virtual Healthcare Conference

Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat and will give a corporate presentation.
Thursday, April 20, 2023 at 12:45 pm EDT
Virtual
Register to view webcast here.
Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Summit

Steven Kelly, President and Chief Executive Officer, and Michael Klichinsky, PhD, Co-Founder and Chief Scientific Officer, will participate in a fireside chat.
Monday, April 24, 2023 at 11:00 am EDT
Virtual
Register to view webcast here.
A replay of webcasts, when available, will be posted and archived at the Company’s Investor Events webpage for a limited time following the event.

On April 6, 2023 Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) reported that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel’s Board of Directors and granted as an inducement material to employees’ entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4) (Press release, Rigel, APR 6, 2023, View Source [SID1234629868]). Specifically, Rigel granted 108,600 stock options to three non-executive employees vesting over four years with a one-year cliff.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

On April 6, 2023 AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, reported the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares ("ADSs"), pre-funded warrants to purchase ADSs and warrants to purchase ADSs (Press release, Anpac Bio, APR 6, 2023, View Source [SID1234629867]). The Company plans to use the net proceeds from the offering for the advancement of our research and development activities, working capital and general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with such offering, the Company sold to the institutional investors a total of 625,000 ADSs priced at $4.00 per ADS, pre-funded warrants exercisable for 125,000 ADSs and warrants exercisable for 750,000 ADSs. The purchase price of each pre-funded warrant is equal to the offering price per ADS, minus $0.0001, and the exercise price of each pre-funded warrant is equal $0.0001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full. The warrants are immediately exercisable, expire five (5) years from the original issuance date and have an exercise price of $4.00 per ADS. The Company also issued to Univest Securities, LLC, which acted as the sole placement agent for the offering, warrants exercisable for 37,500 ADSs, with an exercise price of $4.80.

The gross proceeds to the Company from the registered direct offering were approximately $3.0 million before deducting the placement agent’s fees and other offering expenses.

The ADSs, the pre-funded warrants, the warrants and the ADSs underlying the pre-funded warrants, the warrants and the placement agent’s warrants were offered pursuant to a prospectus supplement to a shelf registration statement on Form F-3 (File No. 333-256630) previously filed and declared effective by the U.S. Securities and Exchange Commission ("SEC") on June 7, 2021 (the "Shelf Registration Statement"). Such offering was made only by means of such prospectus supplement, which was filed by the Company with the SEC on April 4, 2023.

Univest Securities, LLC acted as the sole placement agent for this offering.

On April 6, 2023 Accent Therapeutics, a biopharmaceutical company developing breakthrough, oncology-focused small molecule therapies that target RNA-modifying proteins, reported an upcoming presentation introducing DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida (Press release, Accent Therapeutics, APR 6, 2023, View Source [SID1234629866]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will provide rationale to support targeting inhibitors of DHX9, an RNA helicase which has been reported to play important roles in replication, transcription, translation, RNA processing and maintenance of genomic stability, as a novel therapeutic modality in microsatellite instable (MSI) colorectal cancer (CRC). The presentation will further describe the first identification of potent and selective small molecule inhibitors of DHX9 that demonstrate tumor cell killing in both in vitro and in vivo preclinical cancer models.

The presentation will be available on the Accent website following the meeting.

Details for the presentation are as follows:

Title: Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer
Authors: Jennifer Castro, Matthew H. Daniels, Chuang Lu, David Brennan, Deepali Gotur, Young-Tae Lee, Kevin Knockenhauer, April Case, Jie Wu, Shane M. Buker, Julie Liu, Brian A. Sparling, E. Allen Sickmier, Stephen J. Blakemore, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Scott Ribich, Robert A. Copeland
Accent Therapeutics, Lexington, MA
Abstract Number: 1136
Session Category: Experimental and Molecular Therapeutics
Session Title: Innovative Therapeutic Approaches
Session Date and Time: Sunday, April 16, 2023 3:00 – 5:00 PM ET
Session Location: Room W331, Orange County Convention Center, Orlando, Florida

About DHX9
DHX9 is a multifunctional DEAH-box RNA helicase which has been reported to play important roles in replication, transcription, translation, RNA splicing and RNA processing which contribute to DHX9’s role in maintenance of genomic stability. Overexpression of DHX9 has been observed in multiple cancer types, including colorectal cancer (CRC) and lung cancer. In addition, microsatellite instable (MSI) tumors exhibiting defective mismatch repair (dMMR) show a strong dependence on DHX9, making this helicase an attractive target for oncology drug discovery.

On April 6, 2023 Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported that it will present three posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR) (Free AACR Whitepaper) 2023, taking place April 14-19, 2023, in Orlando, FL (Press release, Aadi Bioscience, APR 6, 2023, View Source [SID1234629865]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the poster presentations are below:

Title: "Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I)"
Date and Time: Monday, April 17, 2023, 9:00 AM – 12:30 PM
Session Title: Phase II and Phase III Clinical Trials in Progress
Presentation Number: CT057

Title: "Synergistic anti-tumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts"
Date and Time: Tuesday, April 18, 2023, 1:30 – 5:00 PM
Session Category: Clinical Research Excluding Trials
Session Title: Poster Combination Therapies for Cancer
Presentation Number: 5484

Title: "Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations"
Date and Time: Wednesday, April 19, 2023, 9:00 AM – 12:30 PM
Session Category: Clinical Research Excluding Trials
Session Title: Late-Breaking Research: Clinical Research 3
Presentation Number: LB288

Full session and meeting details are available through the AACR (Free AACR Whitepaper) Annual Meeting planner: AACR (Free AACR Whitepaper) Annual Meeting 2023 | Meetings | AACR (Free AACR Whitepaper). Following Aadi’s presentation at AACR (Free AACR Whitepaper), the posters will be made available on the investor relations page of the Aadi website at www.aadibio.com